Neuroscience Antibodies and Assays Market Growing Massively by 2019-2025 Focusing on Key Players Thermo Fisher, Abcam, Bio-Rad, Merck, Cell Signaling…

This market report is a thorough analysis of the existing situation and the anticipated condition for the Neuroscience Antibodies and Assays market. Investigation for gathering the content for this report is done in-depth and meticulously. Present scenarios, past progress, global recognition and future prospects of Neuroscience Antibodies and Assays market is offered in this report. Main strategies, market shares, products of the companies and investments in the Neuroscience Antibodies and Assays Market are also mentioned in detail.

The global neuroscience antibodies and assays market can be categorized based on product type, indication, technology, end-user, and region. On the basis of product type, the market can be divided into consumables and instruments. The consumable segment can be sub-divided into reagents (media & sera, stains & dyes, fixatives, buffers, solvents, probes, enzymes, proteins, and peptides), antibodies (primary antibodies, secondary antibodies, and assay. The instruments segment can be further categorized into microplate readers, immunoassay analyzers, and others.

Get Sample Copy of this Report@:

https://www.theresearchcorporation.com/request-sample.php?id=23701

Top Companies Profiled in this Report includes Thermo Fisher, Abcam, Bio-Rad, Merck, Cell Signaling Technology, Genscript

For the purpose of the study, the Global Neuroscience Antibodies and Assays market is segmented based on various parameters. An in-depth regional classification of the market is also included herein. The factors which are impacting the markets growth are studied in detail. The report also presents a round-up of vulnerabilities that companies operating in the market must avoid in order to enjoy sustainable growth through the course of the forecast period.

Market segment by Type, the product can be split into

Consumables

Instruments

Market segment by Application, split into

Pharmaceutical & Biotechnology Companies

Academic & Research Institutes

Hospitals & Diagnostic Centers

Market segment by Regions/Countries, this report covers

United States

Europe

China

Japan

Southeast Asia

India

Central & South America

Get Reasonable Discount on this Premium Report @: https://www.theresearchcorporation.com/ask-for-discount.php?id=23701

Key Question Answered in Report:

What are the top key players of the Global Neuroscience Antibodies and Assays Market?

What are the strengths and weaknesses of the Global Neuroscience Antibodies and Assays Market?

What are the highest competitors in Neuroscience Antibodies and Assays market?

What are the different marketing and distribution channels?

What are the global Neuroscience Antibodies and Assays market opportunities in front of the market?

What are the key outcomes of SWOT and Porters five techniques?

What is the global Neuroscience Antibodies and Assays market size and growth rate in the forecast period?

Table of Contents

Global Neuroscience Antibodies and Assays Market Research Report

Chapter 1 Neuroscience Antibodies and Assays Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Neuroscience Antibodies and Assays Market Forecast

For More Information:

https://www.theresearchcorporation.com/enquiry-before-buying.php?id=23701

Original post:
Neuroscience Antibodies and Assays Market Growing Massively by 2019-2025 Focusing on Key Players Thermo Fisher, Abcam, Bio-Rad, Merck, Cell Signaling...

UNSW graduate receives 2020 inaugural Bob Hawke and Tim Fischer Monash scholarship – UNSW Newsroom

Dr Matthew Lennon was awarded the inaugural 2020 Bob Hawke and Tim Fischer Monash Scholarship at a celebration event held at Parliament House Canberra earlier this month.

It is an incredible honour to receive this scholarship - Tim Fisher and John Monash were both extraordinary men who have distinctively shaped the future of Australia. The scholarship is an opportunity to be part of the great Australian legacy and help shape our future for the better, Dr Lennon said.

The scholarship was created in honour of the late former Prime Minister and the late former National Party leader. The new $10 million scholarship is awarded by the General Sir John Monash Foundation to recipients who show excellence in their field, leadership qualities and a desire to make an important contribution to society.

Dr Lennon will use the scholarship to complete a Master of Neuroscience at Oxford University and plans to bring better dementia research and vital therapeutics, drug trials and care back to Australia to help our ageing population in rural and remote communities.

Dementia is a disease that has touched my family deeply. It is a disease that takes not just ones health but the very identity of the person who lives through it. It is the tragedies both in my family and affecting my patients that has inspired meto work on this vexed area of research, Dr Lennon said.

Dr Lennon graduated from Medicine at UNSW in 2017 with the University Medal and Class I Honours in Neuroscience. Following the completion of his degree he has worked with the Centre for Healthy Brain Ageing to explore epidemiological and genetic risk factors for Alzheimer's Dementia.

While studying at UNSW he started Springboard Education, a charitable tutoring organisation that has provided free tutoring and educational resources to thousands of students in rural Australia.

He has worked extensively within the Australian Medical Association, writing and enacting policy, as well as for the Commonwealth Department of Health and Ageing, working to resolve challenges in Aged Care for rural and remote Australia.

The 2020 Bob Hawke and Tim Fischer John Monash Scholarship was judged by an eminent group of Australians, including former supreme court judges, industry leaders, academics, leaders of business, policy advisors and scientists from around the country, following a rigorous three-stage process.

See original here:
UNSW graduate receives 2020 inaugural Bob Hawke and Tim Fischer Monash scholarship - UNSW Newsroom

BioXcel Therapeutics to Expand Study of BXCL701 into Multiple Advanced Solid Tumor TypesBXCL701 may improve patient response when combined with…

NEW HAVEN, Conn., Dec. 11, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (BTI or the Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that the Company will advance the clinical evaluation of BXCL701 into multiple advanced solid tumors. BXCL701 is an orally active, systemic innate immunity activator with dual mechanisms of action.

This new study allows us to accelerate the evaluation of BXCL701 in combination with a checkpoint inhibitor in patients with a range of tumor types where checkpoint inhibitors are standard of care, commented Vincent J. ONeill, M.D., Senior Vice President and Chief Medical Officer of BTI. We believe BXCL701 may have the potential to extend treatment responses to KEYTRUDA, a PD-1 inhibitor, when used together to treat advanced solid cancers. This trial expands on our studies of BXCL701 in prostate and pancreatic cancers as we explore its full potential.

The open-label Phase 2 basket trial (NCT04171219) will take place at a leading cancer center in the U.S. The study is designed to evaluate the response rate of orally administered BXCL701, combined with Pembrolizumab (KEYTRUDA) in patients with advanced solid cancers. If successful, the study would provide an option for patients who have failed or are refractory to checkpoint therapy. Outcome measures will include progression-free-survival, overall survival, and duration of response, as well as the safety of the combined treatment.

To learn more about the trial, visit https://clinicaltrials.gov/

About BXCL701:

BXCL701 is an investigational orally administered innate immune activator designed to initiate inflammation in the tumor microenvironment. Approved and experimental immunotherapies often struggle to address cancers that appear cold or uninflamed. Therefore, BXCL701 may render cold tumors hot, making them more detectable by the adaptive immune system and thereby facilitating the development of a strong anti-cancer immune response. BTIs data supports BXCL701s synergy with both current checkpoint inhibitor-based therapies and emerging immunotherapies directed to activate T-cells, such as IL-2 and OX40 agonist antibodies.

This candidate is currently being developed as therapy for treatment emergent Neuroendocrine Prostate Cancer (tNEPC) and pancreatic cancer (both cold tumors) and other advanced solid cancers that are hot or have become resistant to checkpoint inhibitors. The safety escalation portion of the trial evaluating the double combination of BXCL701 and KEYTRUDA for tNEPC is ongoing with data read-out expected in the first half of 2020. The FDA has also accepted an IND application for the triple combination of BXCL701, bempegaldesleukin (produced by Nektar Therapeutics, Inc., or Nektar) and BAVENCIO (avelumab, Merck KGaA, Darmstadt, Germany and Pfizer) in pancreatic cancer. The triple combination trial is expected to begin following Nektar and Pfizers safety run-in study of a double combination of bempegaldesleukin and avelumab and the outcome of that trial.

About BioXcel Therapeutics, Inc.:

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer, pancreatic cancer and advanced solid cancers in combination with other immuno-oncology agents. For more information, please visit http://www.bioxceltherapeutics.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to the timing and data from clinical development initiatives and trials for BXCL701 and the potential for BXCL701 to improve or extend treatment responses when combined with checkpoint inhibitors. When used herein, words including anticipate, being, will, plan, may, continue, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon BTI's current expectations and various assumptions. BTI believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain.

BTI may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; its ability to commercialize its product candidates; and the other important factors discussed under the caption Risk Factors in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019 as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SECs website at http://www.sec.gov.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While BTI may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing BTIs views as of any date subsequent to the date of this press release.

Contact Information:

BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com

Investor Relations:John Grazianojgraziano@troutgroup.com1.646.378.2942

Media:Julia Deutschjdeutsch@troutgroup.com1.646.378.2967

Link:
BioXcel Therapeutics to Expand Study of BXCL701 into Multiple Advanced Solid Tumor TypesBXCL701 may improve patient response when combined with...

A tale of two continents: Visiting scholar returns to Hershey to share impact – Penn State News

HERSHEY, Pa. When James Connor, distinguished professor of neuroscience and anatomy and vice chair for research in the Department of Neurosurgery at Penn State College of Medicine, met James Olopade at an International Brain Research Organization (IBRO) meeting in South Africa more than a decade ago, Connor didnt realize that Olopade would someday come to his lab as part of an IBRO Research Fellowship. He also didnt know the impact the fellowship would have on Olopades career and on brain research and education in Africa.

Connor received a Visiting Scholar Speaker Award to Enhance Diversity in Neuroscience from the IBRO, and is using the funds to bring Olopade back to Hershey to share how his experience at the College of Medicine impacted his research and academic efforts in Africa.

Olopade, a veterinarian by training, arrived in Hershey in 2008 with an interest in studying neurotoxicity. During his time in Connors lab, he was able to determine that exposure to vanadium, a toxic metal in the environment in parts of Nigeria, during prenatal development can have negative consequences for brain development.

Students, faculty and staff at the College of Medicine can hear Olopade present his talk, titled The Impact in Africa 10 years After Being Trained in Penn State: The Story of an IBRO Research Fellow Alumnus, at 3 p.m. Thursday, Dec. 12, in Lecture Room A.

Following his time as a visiting scholar at the College of Medicine, Olopade was published multiple times and continued his studies internationally through a series of fellowships. He is a professor of veterinary medicine at the University of Ibadan in Nigeria, his native country. From 2014 to 2018, he was head of the Department of Veterinary Anatomy and, in 2017, was elected dean of the faculty of Veterinary Medicine at the University of Ibadan. He also served as president of the Society of Neuroscientists of Africa and has been published more than 100 times.

James is a true leader in the field of neuroscience, said Connor. He hopes to set up the first neuroscience institute in Africa and he has been influential in fostering research opportunities for learners in Africa.

While in Nigeria a few years ago, Connor learned that students in Africa are responsible for funding their doctoral studies. He said that many students teach and do odd jobs while completing their education, which makes Olopades journey all the more impressive.

James is a role model for aspiring scientists in his country, Connor said. He has helped students find funding to continue their education and mentored them in research.

The goal of the Visiting Scholar Speaker Award is to promote awareness and increase diversity in neuroscience something the Department of Neurosurgery continues to champion as it recruits faculty and trainees from a variety of different backgrounds.

I am proud of our departments efforts to create a diverse environment, said Dr. Robert Harbaugh, chair of the Department of Neurosurgery at the College of Medicine.

According to Lynette Chappell-Williams, chief diversity officer for Penn State Health and associate dean of diversity and inclusion at the College of Medicine, diverse voices in research can help scientists gain new perspectives on topics they may not have previously considered.

Research shows that increased diversity in an organization can drive innovation and excellence, Chappell-Williams said.Dr. Olopades experience is a prime example of how diversity can benefit the field of research and should serve as encouragement to follow the lead of our neurosurgery department in exploring ways to increase cultural diversity in our specialty areas.

See more here:
A tale of two continents: Visiting scholar returns to Hershey to share impact - Penn State News

Anatomy of an upset (was it an upset?) and some flaws exposed – 247Sports

Six games in 13 days. Like it or not, that matters. Thats something betting sharps look at when looking for an edge. It helped explain why Penn State -- an unranked opponent -- came in favored over the No. 4 team in the country. While the home fans chanted overrated in the closing minutes of the Nittany Lions 76-68 upset win Tuesday night, Maryland wont be judged too harshly on this game alone after starting the season with 10 straight victories and surviving without a loss longer than 346 of college basketballs 353 D-I teams (No. 1 Louisville also went down to an unranked opponent tonight).

It was clear they once again didnt bring their A game to the Bryce Jordan Center, an arena that has witnessed a Terps loss four years in a row, and their recent stretch of games combined with Penn States physical play appeared to catch up to them, especially in the final seven minutes as they failed to hit a field goal down the stretch until there was 42 seconds to go. Still, it was a bit perplexing that Terps coach Mark Turgeon reasoned afterward that his team -- which returned seven of its top eight players from a year ago -- has just like five plays we can run at this point in the season.

Weve got a long ways to go offensively, and were struggling a bit, Turgeon said. Hopefully this will refocus us.

The game raised -- and highlighted -- a handful of red flags beyond that. For starters, the slow starts finally caught up to them. The Terps turned it over 12 times in the first 12 minutes as the Nittany Lions raced out to a double digit lead, and many of the giveaways were inexcusable, even when generously factoring in the apparent fatigue. They were the type of mental lapses that could be equated to a still relatively young team feeling a little too confident after recovering from a 15-point deficit to win its Big Ten opener over Illinois Saturday night.

Maryland made far too many lackadaisical passes in the opening frame, and didnt have the legs on either end to repeat their late-game heroics after Anthony Cowans game-tying and game-sealing offensive and defensive plays saved them against the Illini three days earlier. Its hard to ignore the slow-start problem given that it extends back to last year, but Turgeon hasnt expressed much concern publicly, choosing instead to once again laud his team for not sharing the ball well enough tonight, pointing to over-dribbling as the leading cause for the early dysfunction.

We wanted to lead the country in dribbling tonight, he said.

What exacerbated the problems Tuesday night, though, was the Terps lack of depth. Freshman center Makhi Mitchell made his fifth start Tuesday night, but finished scoreless for the third straight game. Ricky Lindo provided solid energy in relief but was pushed around by Penn States frontline, while Serrel Smith and Hakim Hart rode the bench for the entirety of the second half. This is an area where Maryland could improve later in the season if Donta Scott continues to improve and Chol Marial measures up to Turgeons seemingly wishful expectations, but the early returns raise concerns whether any of the Mitchell twins, Lindo, Hart and Serrel Smith are ready to add positive value on a consistent basis this year.

As Turgeon put it, our young guys looked young tonight.

Maryland couldve used another guard off the bench, too, as Eric Ayala, who led the team with 11 points and two assists in the first half, was slowed by cramps and played just 10 minutes in the second. Cowan finished with a team-high 16 points, but was pestered all game long by Big Ten steals leader Jamari Wheeler, turning it over four times and making just five of his 17 field goal attempts. Aaron Wiggins shooting slump, meanwhile, continued -- he shot just 3-12 from the field and 1-6 from three -- while Mike Watkins (15 points, 11 rebounds, four blocks) outplayed Jalen Smith (12 points, 11 rebounds, three blocks) on the block.

As the Terps have found out time and again, Penn State isnt the type of team you want to face as when youre fatigued. Theyre physical, deep and their guards, while not overly talented, push the pace and pressure the ball non-stop. Sophomore guard Izaiah Brockington, who was a starter on the St. Bonaventure team that upset Maryland two years ago, had three steals off the bench. Myles Dread and Myron Jones also poked the ball away a couple of times apiece. Penn State beat up Maryland inside as well. Smith fared well against Lamar Stevens last year, but with Bruno Fernando gone he was forced to guard Watkins, who is nearly five years older and 20 pounds heavier than him.

He looked a step or two slow on rotations almost the entire game, and made just two field goals inside the arc. Stevens matched Watkins in scoring and added 10 rebounds, feasting on Lindo and Scott, whom Turgeon (perhaps regrettably) decided were better options on the 6-foot-8 matchup nightmare than Morsell. Penn State shot 12 percent better than Maryland from inside the arc.

They might have been shaving before my guys were even born, Turgeon joked of Penn States frontcourt.

Morsell started slow after coming off the bench -- he had three early turnovers -- but hit a crucial three to cut the lead to five with less than 12 to go and finished with eight points. Turgeons decision to deploy Lindo and Scott on Stevens led to Marylands five best players -- Cowan, Ayala, Wiggins, Morsell and Jalen Smith -- sharing the court for less than a minute. Its clear Turgeon is still trying to figure out the rotations, but hell probably want to avoid that happening again. Tuesday night doesnt speak to what the Terps can accomplish this season, but it did highlight problems with the teams rotations and depth, especially in the frontcourt.

Turgeon doesnt trust Hart or Serrel Smith enough to play four-guard lineups the entire game, but at the same time a second big hasnt stepped up next to Jalen Smith in the frontcourt. Turgeon went with Morsell at the four in the first month of the season against a schedule that featured mainly undersized teams, but there will be plenty of more frontcourt-heavy teams like Penn State that will force Turgeons hand over the next three months. Playing Morsell alongside Jalen Smith still might be the best option, but its probably safe to say at least one of Lindo, Hart, Marial and the Mitchell twins will have to step up if Maryland wants to handle the day-to-day grind of the Big Ten schedule and compete for a conference championship.

We have a long ways to go as a team and sometimes when you keep winning you dont realize it. Coaches do, Turgeon said, but hopefully tonight because of the loss our guys will realize that we have a ways to go to get where we need to be.

More from Twitter:

Read the original post:
Anatomy of an upset (was it an upset?) and some flaws exposed - 247Sports

Trolls, Sock Puppets and Useful Idiots: An Anatomy of an Election Disinformation Campaign – Byline Times

Photo: Yorkshire Evening Post Peter Jukes dissects how No 10 sources, mainstream broadcast journalists and an army of hired online activists tried to save Boris Johnson from himself. The Local Journalist

First, some facts, as they are in precious short supply. Around noon on Sunday 8 December, Daniel Sheridan of the Yorkshire Evening Post published a story about Jack Williment-Barr, a four-year-old boy who was rushed to Leeds General Infirmary with suspected pneumonia. His mother Sarah had contacted the newspaper with a picture of her son lying on a pile of coats and claimed he had been left in the clinical treatment room for four hours.

Like any responsible journalist, Daniel Sheridan double-checked the story with the hospital and its chief medical officer, Dr Yvette Oade, who explained how busy the hospital was and apologised to the family. We are extremely sorry that there were only chairs available in the treatment room, and no bed, she said. This falls below our usual high standards and for this we would like to sincerely apologise to Jack and his family.

So far, a telling example of the vital importance of local journalism a profession that continues to be gutted as newsrooms are cut or amalgamated, and Google and Facebook siphon off the billions of revenues that keep local accountability alive.

The next day, Joe Pike, a young journalist for ITV Calendar in Grimsby, was following the Conservative Party leader as he posed for photos holding a large cod (not for the first time) in the fishing town which has often become an emblem of taking back control of our waters by leaving the European Union.

Unlike the BBC interviewer Andrew Neil, Joe Pike has no reputation for skewering politicians, so Boris Johnson and his advisors probably thought they didnt need to avoid this particular interview in the bowels of the fish warehouses. They miscalculated. Pike whipped out his phone with the photo of Jack Williment-Barr lying on the floor, and persistently questioned the Prime Minister about it.

In a psychologically revealing panic, Johnson tried to bluster that everything would improve once we got Brexit done. But Pike persisted. Johnson tried to steamroller him, but his darting eyes and demeanour showed that he didnt want to answer the question and, in an effort to avoid it, the Prime Minister took the reporters phone and hid it in his pocket. This prompted one of the most remarkable comments of the campaign so far from Pike who remarked, calmly:

Youve refused to see the photo. Youve taken my phone and put it in your pocket, Prime Minister.

Child psychiatrists would have a field day on this. The failure to realise that hiding your face does not make you invisible, or that stealing a reporters phone does not make the report go away, suggests that under pressure the leader of the Conservative Party has the social cognitive abilities of a four-year-old.

Apart from Johnsons kleptomanic evasion, the film of this strange encounter had the additional problem of focusing on the NHS at a key point in the last few days of the General Election campaign. Conservative campaigners know that the NHS is not their strong point, so the Health and Social Care Minister, Matt Hancock, was dispatched to Leeds General Infirmary to firefight.

As Hancock rushed to Leeds, a host of media figures sympathetic to Johnson rushed into action. Guido Fawkes (which registered the site Boris2020 seven years ago) was first off the mark, with a fake story that 100 Labour activists were being paid to go to Leeds to protest. This was followed up by his former colleague at the Sun, Tom Newton Dunn, who described a flash mob descending.

Soon, the BBCs political editor, Laura Kuenssberg, was describing to her 1.1 million followers how Labour activists scrambled to go and protest and then it turned nasty when one of them punched Hancocks adviser. The information had no attribution, or Ive heard or sources say.

Not to be left out, Robert Peston, the political editor of the second largest broadcaster, ITV, identified the person punched to his 1 million followers, and named the special adviser to Matt Hancock, adding that the police had been called.

The only problem with this breaking story which quickly and conveniently replaced the story of Johnson pocketing the reporters phone in all the major news feeds was that it was completely bogus.

There were about four noisy demonstrators outside Leeds General Infirmary as Hancock departed in his ministerial car, not 100. No punch was ever landed. Hancocks SpAd walked into a cyclists hand as he pointed to the ministerial car rushing away.

It took several hours of persistent correction from other Twitter users before both Peston and Kuenssberg corrected the damaging allegation of assault. But their apologies revealed even more

Peston explained that he had been told the story by two Tory party sources. According to good journalistic practice, that would be the minimum to run an allegation of assault but only if the sources were independent. They clearly werent. What would have been a rookie mistake for a young journalist was a catastrophic failure of judgement by the political editors of both major broadcasters, made even more so because it came in the crucial last few days of a landmark General Election.

Im not of the the view that either Peston or Kuenssberg are consciously partisan, and I certainly dont buy the allegation that they have been bought. But they have been played, and to rescue their reputations and most importantly our trust in the two most important sources of news in the country there should be a full inquiry.

For the real culprits here are the sources who lied to them both, consistently. They have no protection for deceiving the public and both Peston and Kuenssberg have a public duty to tell us who they are. Nothing short of that can begin to repair the damage caused.

Thanks to some brilliant traffic and network analysis by Mark Owen Jones, we can see how the fake punch story was spread around 7,500 Twitter interactions from 5,500 unique Twitter accounts from Guido Fawkes, via the Suns chief political correspondent, commentator Dan Hodges to the BBC and ITV. But that wasnt the end of the story.

Soon after the punch story was discredited, a new story about the whole hospital photo being staged borrowed from Facebook began doing the rounds on Twitter.

All the Twitter accounts repeating it had the same information a good friend of mine is a senior nursing sister and claimed that the mother of Jack Williment-Barr had faked the photo for publicity as a Labour activist.

This frankly defamatory and unpleasant smear was boosted, with no fact-checking, by Allison Pearson of the Telegraph and Brexit Party MEP Claire Fox. Just one post on one Facebook discussion group alone has 276 comments and 98 shares.

No sooner was this story being debunked (after all, the head of the Leeds hospital trust had apologised two days previously) when a new disinformation theme was being boosted on social media, especially to the gullible Allison Pearson, who declared she was going to write a story in the Telegraph about the shocking propaganda around the four-year-old.

Whoever this Great Ormond St nurse was, they seemed to have multiple Twitter accounts in fake names.

The first tweet came from a Twitter user who claimed to have attended six universities and was now training in law:

The next came from a foreign exchange trader:

While another, identical claim, came from someone who had previously boasted about working in supply chain JLR for 35 years:

Whether these are semi-automated bots, or one malicious user deploying sock puppet accounts, or just bad faith actors in the public realm, they are very effective at targeting journalists and commentators who then spread the false narrative to a wider audience.

In fact, journalists and politicians are the main targets of such information operations, whether organised centrally or not, as trusted but duped sources are the quickest way to amplify a misleading story.

Britain is currently undergoing a perfect storm of electoral interference. With lax or unenforceable legislation about non-party campaigners spending millions on Facebook posts, and with Twitter easily gamed by trolls, bots and sock puppets, the online sphere requires extreme caution.

We should only trust journalists who seek to verify and double-check, like Daniel Sheridan who started this saga, and remember that we are all easy prey to the stories we want to hear.

Combating online disinformation requires education, some ferocious forensic investigators, and a large dose of mockery and shame to those involved. But what to do with our press?

Both the Sun and the Telegraph were keen to promote and prop up these fake stories. Though their circulations are tanking and their profit margins non-existent, these newspapers still wield power, especially over politicians, whose lives they can trash, mock or ignore.

But, by far, the most worrying thing is our two main broadcasters the BBC and ITV. One of the protections against our feral press was that we had a mixed commercial and public service broadcast system which could be relatively immune to political and commercial pressure.

Kuenssberg and Peston have shown the other hidden danger: the danger of client journalism, of editors in hock to their sources thanks to the clubbish cliqueness of the lobby system of unattributed briefings. I personally think that there is some cultural capture here, because youre only two north London dinner parties away from another senior journalist or politician these days, thanks to rank inaccessibility of media jobs for most ordinary people. But, more important than any professional criticism of the two political editors, is the laxity and complicity of their management.

Byline Times approached the BBC last night for a response to Laura Kuenssbergs misinformation. We asked the broadcaster how its political editor happened to circulate a false rumour as a fact and how this reflected on the corporations editorial standards and the public service broadcasters reputation. The press office replied with a curt message directing us to her apology an apology that raises more questions than it answers and does nothing to allay the growing concern of licence fee payers.

Byline Times is still waiting for a response from ITV.

This article was corrected to reflect that Joe Pike wont be joining Sky News until January and is still employed by ITV Calendar.

Here is the original post:
Trolls, Sock Puppets and Useful Idiots: An Anatomy of an Election Disinformation Campaign - Byline Times

‘Grey’s Anatomy’ Fans Hate Meredith’s New Love Interest, But Not For the Reason You Think – Showbiz Cheat Sheet

The world has long been mourning the death of Doctor Derek Shepherd. Okay, maybe just Greys Anatomy fans have been missing the swoon-worthy McDreamy. Either way, a new love interest for Ellen Pompeos Meredith Grey has been a long time coming.

However, fans are disapproving of this seasons potential fling and its been hard to sell them on the Derek Shepherd replacement.

Thinking back to when Derek (Patrick Dempsey) was still alive, their relationship, however fairy tale worthy, still had its share of ups and downs. Lots and lots of ups and downs. The entire series (and their ill-fated relationship) began when Meredith and Derek met at a bar near the hospital where he was an attending doctor and she just starting as an intern.

Unfortunately for Meredith, Derek was already married. Thus began their roller-coaster romance.

Between the drama of simply working together, to Dereks attempts to work things out with his wife, they had a slow start to a successful relationship. Although the two eventually got (post-it note) married and started a family together, his untimely death in season 11 left Meredith heartbroken and on her own again.

There have been some dates and Merediths signature one-night stands since then. For instance, Meredith dated Dr. Will Thorpe in Season 12, soon after Dereks passing. In fact, he was the first guy shed dated since her husbands death. Ultimately, thats why a relationship didnt work out between the two, because Meredith was still too broken. Will seemed like a nice guy and even said he would wait for her. But, that is yet to be seen.

That same season Meredith spent some time with Nathan Riggs, but his fiance, Megan, came back into the picture unexpectedly and Meredith encouraged him to reunite with Megan.

Season 15 brought some changes for Meredith. Most notably, her efforts to get back into the dating scene. At the beginning of the season she went on one blind date with John, played by fan-favorite Josh Radnor.

Unfortunately, he complained about dating desperate single moms and that was then end of that.

But, despite the bad date, this was the start of Merediths quest for new love.

We thought it would just be a diehard loyalty to Derek which would keep fans from embracing Merediths new man. But, thats not the only reason viewers arent supportive of Merediths new relationship with Andrew DeLuca. As season 16 plays out, it will be interesting to see if viewers are able to get behind this budding romance.

Reddit user Crazycatgirl16 points out that writers seem to use new characters to spice up a boring plot line. they pull out the lets introduce a new character card even though we have a big enough cast already.

She laments on a message board dedicated to dissecting the lack of originality in recent episodes of Greys. Other common complaints on the thread include too many surprise pregnancies and an overuse of the love triangle plot line.

Both of these complaints hit home on the Deluca front. Not only was he a new character in the show for Season 15, but he also was one of two men vying for Mers affection. The triangle existed between Meredith, Deluca, and Link. Ultimately, Deluca is the lucky winner of Merediths heart. For now.

Some fans have been turned to the Deluca side, perhaps more will be swayed as the season continues.

Greys Anatomy has been renewed for both Season 16 and 17, well see how long the MerLuca relationship lasts.

Read this article:
'Grey's Anatomy' Fans Hate Meredith's New Love Interest, But Not For the Reason You Think - Showbiz Cheat Sheet

The Crown would pull a Greys Anatomy at the SAG Awards with a win for Olivia Colman – Gold Derby

Olivia Colman is trying to follow in Claire Foys footsteps in more ways than one. Succeeding her as Queen Elizabeth II on The Crown is one thing and now shes attempting to emulate her awards run for the show. Colman is the heavy favorite to take home the Best TV Drama Actress Golden Globe and Screen Actors Guild Awards, just like Foy did, and a win at the latter would put The Crown in the company of just one other show to field two different winners in the category.

Thanks to Foys back-to-back wins in 2017-18, The Crown is one of eight shows to garner multiple SAG Awards in the lead actress category. But seven of those series had their same respective star score repeat victories; the only show to boast two different winners is Greys Anatomy, which saw Sandra Oh and Chandra Wilson triumph back to back in 2006 and 07.

SEE The Crowns Olivia Colman looks to reign supreme with a pristine 3-for-3 Golden Globe record

Those Greys wins are also notable for the fact that Oh and Wilson were supporting players on the long-running medical drama and managed to prevail in the SAG Awards single individual TV races that combine lead and supporting performances. Unlike Foy and Colman on The Crown, Oh and Wilson were co-stars who shared the screen as well, so a Colman victory would be the first instance of the same character winning the SAG Award for two actresses.

Colman is way out in front in our odds at 82/25. Emmy champ Jodie Comer (Killing Eve) is second, followed by Meryl Streep (Big Little Lies), Nicole Kidman (Big Little Lies) and Elisabeth Moss (The Handmaids Tale). Ironically, Comers co-star and defending champ Oh, who is the second person after Julianna Margulies to win this award for two shows, is expected to miss out this year, sitting in sixth place.

Here are all the shows with multiple TV drama actress wins.

3 winsThe Sopranos (all for Edie Falco, 2000, 03, 08)

2 winsThe X-Files (all for Gillian Anderson, 1996-97)ER (all for Julianna Margulies, 1998-99)The West Wing (all for Allison Janney, 2001-02)Greys Anatomy (one for Sandra Oh, 2006; one for Chandra Wilson, 07)The Good Wife (all for Julianna Margulies, 2010-11)How to Get Away with Murder (all for Viola Davis, 2015-16)The Crown (all for Claire Foy, 2017-18)

PREDICTthe SAG Awards nominations; change them until December 11

Be sure tomake your SAG Awards nominee predictionstoday so that Hollywood insiders can see how their TV shows and performers are faring in our odds. You can keep changing your predictions as often as you like until just before nominees are announced on December 11. And join in the fun debate over the 2020 SAG Awards taking place right now with Hollywood insiders inour television forums. Read more Gold Derbyentertainment news.

SIGN UPfor Gold Derbys free newsletter with latest predictions

View original post here:
The Crown would pull a Greys Anatomy at the SAG Awards with a win for Olivia Colman - Gold Derby

Greys Anatomy: What happened to Dr Izzie Stevens? Why did Katherine Heigl leave? – Express

While there is plenty of drama on camera, there was a lot going on behind the scenes as well.

Heigl was nominated for an Emmy Award in 2008 for her performance in Greys Anatomy but she turned down the nomination.

Speaking to The New York Times about why she did this, she said: I did not feel that I was given the material this season to warrant an Emmy nomination and in an effort to maintain the integrity of the academy organization, I withdrew my name from contention.

In addition, I did not want to potentially take away an opportunity from an actress who was given such materials.

Read more:
Greys Anatomy: What happened to Dr Izzie Stevens? Why did Katherine Heigl leave? - Express

Fishy genetics: A behind-the-scenes look at UCD’s Area 52 – Siliconrepublic.com

Jens Carlsson of the UCD School of Biology is co-founder of the Area 52 research group that aims to solve a variety of genetic questions.

After completing his PhD in 2001, followed by a stint at the Danish Institute for Freshwater Research in Silkeborg, assistant professor Jens Carlsson travelled to the US in 2002 to work as a postdoc at the Virginia Institute for Marine Science.

In 2007, he was appointed a visiting associate professor at Duke University, North Carolina, to research the population structure of striped sea bass.

In 2009, he travelled to Ireland to work at University College Cork as a senior research fellow, which included work on deep sea vessels. Then, in 2012, he made the move to University College Dublin and established his research group, Area 52.

Too many people have been watching the CSI TV series and have strange ideas of how a modern genetics laboratory works JENS CARLSSON

I think I have had an interest in fish since I was introduced to fishing as a kid. While completing my BSc project, I was fascinated by the questions you could ask and answer using scientific approaches.

The freedom that academic research has for coming up with projects and then sourcing funding, to actually examine these questions, was probably the reason why I stayed on in science.

The research group Area 52 quickly developed when I started working in UCD. It is now a rather diverse group and we take on research questions from a wide range of disciplines from viral diseases in fish to identification of human remains.

It is the use of genetic methods that allows us to work with these very diverse questions and, so far, all organisms have DNA or RNA so there are a huge variety of questions that we can address.

This also means that we collaborate with a large number of colleagues. While we have the genetic expertise, we also need to work with people who understand the biology and ecology of the organisms.

When Area 52 started, it was only myself and my wife and lab manager in the lab group. But now it has grown significantly and consists of undergraduates, summer interns, visiting students, MSc students, PhD candidates, postdocs, research fellows and research scientists.

I believe that genetics has the capacity to answer questions that no other research field can do.

For example, when you look at marine fish, there are no clear barriers preventing different populations from mixing. However, this does not mean that the fish all belong to the same biological unit or population.

While fish from multiple biological units can mix at feeding areas, they often return to specific spawning sites with each spawning site representing a single biological unit.

Multiple species have been shown using genetics separated into different populations to represent different biological units. This has profound implications for the management of fisheries species, as the level where management needs to take place is natural biological units and this might differ depending on the time of the year.

You might have multiple populations mixing at feeding grounds and it is very difficult to say which fish came from which population when being caught in commercial fisheries as they tend to look the same. However, by using genetic tools we are able to say which individual belongs to which population.

Furthermore, Area 52 has a strong focus on developing non-invasive sampling methods for studies of terrestrial mammals such as elephants, zebras and giraffes primarily in Kenya.

It is often very difficult and invasive to collect genetic material for these animals. We focus on using scat samples that are completely non-invasive. The animal does its business and we collect the scat and use that as source of genetic material.

Area 52 often works with method development and these methods can obviously be used in the commercial world. For example, the management of fisheries species and the integrity of supply chains.

However, the main focus of the lab is in deploying the methods we develop in conservation and environmental monitoring of water ecosystems.

It is always difficult to find time to do the research. You are teaching, mentoring, doing research and administration. At the same time, you need to secure funding for your research and that is difficult.

This is not only because of the lack of time, but also because of the strong competition among researchers for the very limited funding. This means that you can spend significant time on writing a grant application and then it is not funded. I wish the success rate of grants would be higher.

Too many people have been watching the CSI TV series and have strange ideas of how a modern genetics laboratory works.

The big question is climate change and how that will affect distribution and survival of species. This is a very important question requiring collaboration among a large number of researchers from many different fields of science.

Are you a researcher with an interesting project to share? Let us know by emailing editorial@siliconrepublic.com with the subject line Science Uncovered.

See the article here:
Fishy genetics: A behind-the-scenes look at UCD's Area 52 - Siliconrepublic.com